3-(azetidin-1-ylcarbonyl)-1-benzhydrylazetidine | 928038-41-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(azetidin-1-ylcarbonyl)-1-benzhydrylazetidine
• 英文别名: azetidin-1-yl-(1-benzhydrylazetidin-3-yl)methanone
• CAS: 928038-41-9
• 化学式: C₂₀H₂₂N₂O
• 分子量: 306.407
• InChiKey: VQGUPKQMKGPSEE-UHFFFAOYSA-N

物化性质

• 沸点：
  455.8±45.0 °C(Predicted)
• 密度：
  1.208±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(azetidin-1-ylcarbonyl)-1-benzhydrylazetidine 在 palladium 10% on activated carbon lithium aluminium tetrahydride 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 60.0 ℃ 、400.01 kPa 条件下， 反应 14.25h， 生成 N-{4-[(2-{[3-(Azetidin-1-ylmethyl)azetidin-1-ylcarbonyl]amino}pyridin-4-yl)oxy]-2,5-difluorophenyl }-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
  参考文献：
  名称：

  NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3)

  摘要：

  公开号：

  EP1889836B1
• 作为产物：
  描述：

  1-二苯甲基-3-氰基氮杂环丁烷 在 氢氧化钾 、 水 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 乙二醇甲醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 28.0h， 生成 3-(azetidin-1-ylcarbonyl)-1-benzhydrylazetidine
  参考文献：
  名称：

  NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3)

  摘要：

  公开号：

  EP1889836B1

文献信息

• Process for preparing phenoxypyridine derivatives
  申请人：Nagai Mitsuo

  公开号：US20080214815A1

  公开（公告）日：2008-09-04

  A process for preparing a compound represented by the formula (I): comprising reacting a compound represented by the formula (II) or salt thereof: with a compound represented by the formula (III): in the presence of a condensation reagent, wherein R 1 represents 1) optionally substituted azetidin-1-yl, 2) optionally substituted pyrrolidin-1-yl, 3) optionally substituted piperidin-1-yl, etc.; R 2 , R 3 , R 4 and R 5 may be the same or different and each represents hydrogen or fluorine; and R 6 represents hydrogen or fluorine.

  制备一种由化学式(I)表示的化合物的方法： 包括将由化学式(II)表示的化合物或其盐： 与由化学式(III)表示的化合物： 在缩合试剂的存在下反应， 其中R 1 代表1）可选择地取代的氮杂环丙烷-1-基，2）可选择地取代的吡咯烷-1-基，3）可选择地取代的哌啶-1-基等；R 2 ，R 3 ，R 4 和R 5 可以相同也可以不同，每个代表氢或氟；而R 6 代表氢或氟。
• Novel pyridine derivatives and pyrimidine derivatives (3)
  申请人：Matsushima Tomohiro

  公开号：US20080319188A1

  公开（公告）日：2008-12-25

  A compound represented by the following formula, a salt thereof or a hydrate of the foregoing has an excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity and cancer metastasis inhibitory activity. [R 1 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; R 2 and R 3 represent hydrogen; R 4 , R 5 , R 6 , and R 7 may be the same or different and each represents hydrogen, halogen, C 1-6 alkyl or the like; R 8 represents hydrogen or the like; R 9 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; n represents an integer of 1 or 2; X represents —CH═, nitrogen or the like.]

  以下化合物，其盐或水合物，具有优异的肝细胞生长因子受体（HGFR）抑制活性，表现出抗肿瘤活性、抑制血管生成活性和癌症转移抑制活性。[其中，R1代表3-至10-成员的非芳香族杂环基团等；R2和R3代表氢；R4、R5、R6和R7可以相同或不同，每个代表氢、卤素、C1-6烷基或类似物；R8代表氢或类似物；R9代表3-至10-成员的非芳香族杂环基团等；n代表1或2的整数；X代表-CH═，氮或类似物。]
• NOVEL PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3)
  申请人：MATSUSHIMA Tomohiro

  公开号：US20100075944A1

  公开（公告）日：2010-03-25

  A compound represented by the following formula, or a salt thereof or a hydrate of the foregoing, has excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity, and cancer metastasis inhibitory activity. R 1 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; R 2 and R 3 represent hydrogen; R 4 , R 5 , R 6 , and R 7 may be the same or different and each represents hydrogen, halogen, C 1-6 alkyl or the like; R 8 represents hydrogen or the like; R 9 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; n represents an integer of 1 or 2; X represents —CH═, nitrogen or the like.

  以下化合物的分子式，或其盐或水合物，具有出色的肝细胞生长因子受体（HGFR）抑制活性，并表现出抗肿瘤活性、抑制血管生成活性和癌症转移抑制活性。其中，R1代表3-10个成员的非芳香杂环基团等；R2和R3代表氢；R4、R5、R6和R7可以相同也可以不同，每个代表氢、卤素、C1-6烷基或类似物；R8代表氢或类似物；R9代表3-10个成员的非芳香杂环基团等；n代表1或2的整数；X代表-CH═、氮或类似物。
• Pyridine derivatives and pyrimidine derivatives (3)
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US07855290B2

  公开（公告）日：2010-12-21

  A compound represented by the following formula, a salt thereof or a hydrate of the foregoing has an excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity and cancer metastasis inhibitory activity. [R1 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; R2 and R3 represent hydrogen; R4, R5, R6, and R7 may be the same or different and each represents hydrogen, halogen, C1-6 alkyl or the like; R8 represents hydrogen or the like; R9 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; n represents an integer of 1 or 2; X represents —CH═, nitrogen or the like.]

  以下化合物的公式，其盐或其水合物具有出色的肝细胞生长因子受体（HGFR）抑制活性，并表现出抗肿瘤活性、抑制血管生成活性和癌症转移抑制活性。[R1代表3-至10-成员非芳香杂环基团或类似物；R2和R3代表氢；R4、R5、R6和R7可以相同也可以不同，每个代表氢、卤素、C1-6烷基或类似物；R8代表氢或类似物；R9代表3-至10-成员非芳香杂环基团或类似物；n表示1或2；X表示-CH═、氮或类似物。]
• METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2058302A1

  公开（公告）日：2009-05-13

  A process for preparing a compound represented by the formula (I): comprising reacting a compound represented by the formula (II) or salt thereof: with a compound represented by the formula (III): in the presence of a condensation reagent, wherein R1 represents 1) optionally substituted azetidin-1-yl, 2) optionally substituted pyrrolidin-1-yl, 3) optionally substituted piperidin-1-yl, etc.; R2, R3, R4 and R5 may be the same or different and each represents hydrogen or fluorine; and R6 represents hydrogen or fluorine.

  一种制备式 (I) 所代表化合物的工艺： 包括使式 (II) 所代表的化合物或其盐发生反应： 与式 (III) 所代表的化合物反应： 在缩合试剂存在下进行反应、 其中 R1 代表 1）任选取代的氮杂环丁烷-1-基，2）任选取代的吡咯烷-1-基，3）任选取代的哌啶-1-基等；R2、R3、R4 和 R5 可以相同或不同，各自代表氢或氟；R6 代表氢或氟。